Gliomas are the most common malignancies of the central nervous system. Because of tumor localization and the biological behavior of tumor cells, gliomas are characterized by very poor prognosis. Despite significant efforts that have gone into glioma research in recent years, the therapeutic efficacy of available treatment options is still limited, and only a few clinically usable diagnostic biomarkers are available. More and more studies suggest non-coding RNAs to be promising diagnostic biomarkers and therapeutic targets in many cancers, including gliomas. One of the largest groups of these molecules is long non-coding RNAs (lncRNAs). LncRNAs show promising potential because of their unique tissue expression patterns and regulatory functions in cancer cells. Understanding the role of lncRNAs in gliomas may lead to discovery of the novel molecular mechanisms behind glioma biological features. It may also enable development of new solutions to overcome the greatest obstacles in therapy of glioma patients. In this review, we summarize the current knowledge about lncRNAs and their involvement in the molecular pathology of gliomas. A conclusion follows that these RNAs show great potential to serve as powerful diagnostic, prognostic, and predictive biomarkers as well as therapeutic targets.

Central European Institute of Technology Masaryk University 62500 Brno Czech Republic

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Faculty of Medicine Masaryk University 62500 Brno Czech Republic

Department of Neurosurgery University Hospital Brno Faculty of Medicine Masaryk University 62500 Brno Czech Republic

Department of Neurosurgery University Hospital Ostrava 70852 Ostrava Czech Republic

See more in PubMed

Goodenberger M.L., Jenkins R.B. Genetics of adult glioma. Cancer Genet. 2012;205:613–621. doi: 10.1016/j.cancergen.2012.10.009. PubMed DOI

Louis D.N., Perry A., Reifenberger G., von Deimling A., Figarella-Branger D., Cavenee W.K., Ohgaki H., Wiestler O.D., Kleihues P., Ellison D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol. 2016;131:803–820. doi: 10.1007/s00401-016-1545-1. PubMed DOI

Delgado-Lopez P.D., Corrales-Garcia E.M. Survival in glioblastoma: A review on the impact of treatment modalities. Clin. Transl. Oncol. 2016;18:1062–1071. doi: 10.1007/s12094-016-1497-x. PubMed DOI

Miller C.R., Perry A. Glioblastoma. Arch. Pathol. Lab. Med. 2007;131:397–406. PubMed

Ohgaki H., Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 2005;64:479–489. doi: 10.1093/jnen/64.6.479. PubMed DOI

Stupp R., Taillibert S., Kanner A.A., Kesari S., Steinberg D.M., Toms S.A., Taylor L.P., Lieberman F., Silvani A., Fink K.L., et al. Maintenance Therapy with Tumor-Treating Fields Plus Temozolomide vs. Temozolomide alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 2015;314:2535–2543. doi: 10.1001/jama.2015.16669. PubMed DOI

Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., et al. European Organisation for Research, Treatment of Cancer; Brain, Radiation Oncology, National Cancer Institute of Canada Clinical Trials. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–466. PubMed

Lakomy R., Fadrus P., Slampa P., Svoboda T., Kren L., Lzicarova E., Belanova R., Sikova I., Poprach A., Schneiderova M., et al. Multimodal treatment of glioblastoma multiforme: Results of 86 consecutive patients diagnosed in period 2003–2009. Klin. Onkol. 2011;24:112–120. PubMed

Ohgaki H., Kleihues P. The definition of primary and secondary glioblastoma. Clin. Cancer Res. 2013;19:764–772. doi: 10.1158/1078-0432.CCR-12-3002. PubMed DOI

Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110. doi: 10.1016/j.ccr.2009.12.020. PubMed DOI PMC

Agnihotri S., Gajadhar A.S., Ternamian C., Gorlia T., Diefes K.L., Mischel P.S., Kelly J., McGown G., Thorncroft M., Carlson B.L., et al. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J. Clin. Investig. 2012;122:253–266. doi: 10.1172/JCI59334. PubMed DOI PMC

Lee S.Y. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3:198–210. doi: 10.1016/j.gendis.2016.04.007. PubMed DOI PMC

Sanson M., Marie Y., Paris S., Idbaih A., Laffaire J., Ducray F., El Hallani S., Boisselier B., Mokhtari K., Hoang-Xuan K., et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J. Clin. Oncol. 2009;27:4150–4154. doi: 10.1200/JCO.2009.21.9832. PubMed DOI

Van Bakel H., Hughes T.R. Establishing legitimacy and function in the new transcriptome. Briefs Funct. Genomic Proteomic. 2009;8:424–436. doi: 10.1093/bfgp/elp037. PubMed DOI

Spizzo R., Almeida M.I., Colombatti A., Calin G.A. Long non-coding RNAs and cancer: A new frontier of translational research? Oncogene. 2012;31:4577–4587. doi: 10.1038/onc.2011.621. PubMed DOI PMC

Gao Y.F., Wang Z.B., Zhu T., Mao C.X., Mao X.Y., Li L., Yin J.Y., Zhou H.H., Liu Z.Q. A critical overview of long non-coding RNA in glioma etiology 2016: An update. Tumour Biol. 2016 doi: 10.1007/s13277-016-5307-4. PubMed DOI

Derrien T., Johnson R., Bussotti G., Tanzer A., Djebali S., Tilgner H., Guernec G., Martin D., Merkel A., Knowles D.G., et al. The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression. Genome Res. 2012;22:1775–1789. doi: 10.1101/gr.132159.111. PubMed DOI PMC

Ponting C.P., Oliver P.L., Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136:629–641. doi: 10.1016/j.cell.2009.02.006. PubMed DOI

Guil S., Esteller M. Cis-acting noncoding RNAs: Friends and foes. Nat. Struct. Mol. Biol. 2012;19:1068–1075. doi: 10.1038/nsmb.2428. PubMed DOI

Gupta R.A., Shah N., Wang K.C., Kim J., Horlings H.M., Wong D.J., Tsai M.C., Hung T., Argani P., Rinn J.L., et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464:1071–1076. doi: 10.1038/nature08975. PubMed DOI PMC

Iyer M.K., Niknafs Y.S., Malik R., Singhal U., Sahu A., Hosono Y., Barrette T.R., Prensner J.R., Evans J.R., Zhao S., et al. The landscape of long noncoding RNAs in the human transcriptome. Nat. Genet. 2015;47:199–208. doi: 10.1038/ng.3192. PubMed DOI PMC

Li Q., Jia H., Li H., Dong C., Wang Y., Zou Z. LncRNA and mRNA expression profiles of glioblastoma multiforme (GBM) reveal the potential roles of lncRNAs in GBM pathogenesis. Tumour Biol. 2016;37:14537–14552. doi: 10.1007/s13277-016-5299-0. PubMed DOI

Zhang J.X., Han L., Bao Z.S., Wang Y.Y., Chen L.Y., Yan W., Yu S.Z., Pu P.Y., Liu N., You Y.P., et al. Chinese Glioma Cooperative Group. HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma. Neuro-Oncology. 2013;15:1595–1603. doi: 10.1093/neuonc/not131. PubMed DOI PMC

Zhang K., Sun X., Zhou X., Han L., Chen L., Shi Z., Zhang A., Ye M., Wang Q., Liu C., et al. Long non-coding RNA HOTAIR promotes glioblastoma cell cycle progression in an EZH2 dependent manner. Oncotarget. 2015;6:537–546. doi: 10.18632/oncotarget.2681. PubMed DOI PMC

Zhou X., Ren Y., Zhang J., Zhang C., Zhang K., Han L., Kong L., Wei J., Chen L., Yang J., et al. HOTAIR is a therapeutic target in glioblastoma. Oncotarget. 2015;6:8353–8365. PubMed PMC

Huang K., Sun J., Yang C., Wang Y., Zhou B., Kang C., Han L., Wang Q. HOTAIR upregulates an 18-gene cell cycle-related mRNA network in glioma. Int. J. Oncol. 2017 doi: 10.3892/ijo.2017.3901. PubMed DOI

Sun G., Wang Y., Zhang J., Lin N., You Y. MiR-15b/HOTAIR/p53 form a regulatory loop that affects the growth of glioma cells. J. Cell Biochem. 2018;119:4540–4547. doi: 10.1002/jcb.26591. PubMed DOI

Ma X., Li Z., Li T., Zhu L., Li Z., Tian N. Long non-coding RNA HOTAIR enhances angiogenesis by induction of VEGFA expression in glioma cells and transmission to endothelial cells via glioma cell derived-extracellular vesicles. Am. J. Transl. Res. 2017;9:5012–5021. PubMed PMC

Zhao H., Peng R., Liu Q., Liu D., Du P., Yuan J., Peng G., Liao Y. The lncRNA H19 interacts with miR-140 to modulate glioma growth by targeting iASPP. Arch. Biochem. Biophys. 2016;610:1–7. doi: 10.1016/j.abb.2016.09.014. PubMed DOI

Shi Y., Wang Y., Luan W., Wang P., Tao T., Zhang J., Qian J., Liu N., You Y. Long non-coding RNA H19 promotes glioma cell invasion by deriving miR-675. PLoS ONE. 2014;9:e86295. doi: 10.1371/journal.pone.0086295. PubMed DOI PMC

Chen L., Wang Y., He J., Zhang C., Chen J., Shi D. Long non-coding RNA H19 promotes proliferation and invasion in human glioma cells by downregulating miR-152. Oncol. Res. 2018 doi: 10.3727/096504018X15178768577951. PubMed DOI PMC

Wang Q., Zhang J., Liu Y., Zhang W., Zhou J., Duan R., Pu P., Kang C., Han L. A novel cell cycle-associated lncRNA, HOXA11-AS, is transcribed from the 5-prime end of the HOXA transcript and is a biomarker of progression in glioma. Cancer Lett. 2016;373:251–259. doi: 10.1016/j.canlet.2016.01.039. PubMed DOI

Cui Y., Yi L., Zhao J.Z., Jiang Y.G. Long Noncoding RNA HOXA11-AS Functions as miRNA Sponge to Promote the Glioma Tumorigenesis Through Targeting miR-140-5p. DNA Cell. Biol. 2017;36:822–828. doi: 10.1089/dna.2017.3805. PubMed DOI

Lv Q.L., Hu L., Chen S.H., Sun B., Fu M.L., Qin C.Z., Qu Q., Wang G.H., He C.J., Zhou H.H. A Long Noncoding RNA ZEB1-AS1 Promotes Tumorigenesis and Predicts Poor Prognosis in Glioma. Int. J. Mol. Sci. 2016;17:1431. doi: 10.3390/ijms17091431. PubMed DOI PMC

Wang Y., Wang Y., Li J., Zhang Y., Yin H., Han B. CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling. Cancer Lett. 2015;367:122–128. doi: 10.1016/j.canlet.2015.03.027. PubMed DOI

Chen Y., Wu J.J., Lin X.B., Bao Y., Chen Z.H., Zhang C.R., Cai Z., Zhou J.Y., Ding M.H., Wu X.J., et al. Differential lncRNA expression profiles in recurrent gliomas compared with primary gliomas identified by microarray analysis. Int. J. Clin. Exp. Med. 2015;8:5033–5043. PubMed PMC

Kiang K.M., Zhang X.Q., Zhang G.P., Li N., Cheng S.Y., Poon M.W., Pu J.K., Lui W.M., Leung G.K. CRNDE Expression Positively Correlates with EGFR Activation and Modulates Glioma Cell Growth. Target Oncol. 2017;12:353–363. doi: 10.1007/s11523-017-0488-3. PubMed DOI

Li D.X., Fei X.R., Dong Y.F., Cheng C.D., Yang Y., Deng X.F., Huang H.L., Niu W.X., Zhou C.X., Xia C.Y., et al. The long non-coding RNA CRNDE acts as a ceRNA and promotes glioma malignancy by preventing miR-136-5p-mediated downregulation of Bcl-2 and Wnt2. Oncotarget. 2017;8:88163–88178. doi: 10.18632/oncotarget.21513. PubMed DOI PMC

Ma C.C., Xiong Z., Zhu G.N., Wang C., Zong G., Wang H.L., Bian E.B., Zhao B. Long non-coding RNA ATB promotes glioma malignancy by negatively regulating miR-200a. J. Exp. Clin. Cancer Res. 2016;35:90. doi: 10.1186/s13046-016-0367-2. PubMed DOI PMC

Li Z., Liu Y.-H., Diao H.-Y., Ma J., Yao Y.-L. Long noncoding RNA NEAT1 promotes glioma pathogenesis by regulating miR-449b-5p/c-Met axis. Tumour Biol. 2016;37:673–683. PubMed

Zhou K., Zhang C., Yao H., Zhang X., Zhou Y., Che Y., Huang Y. Knockdown of long non-coding RNA NEAT1 inhibits glioma cell migration and invasion via modulation of SOX2 targeted by miR-132. Mol. Cancer. 2018;17:105. doi: 10.1186/s12943-018-0849-2. PubMed DOI PMC

Vassallo I., Zinn P., Lai M., Rajakannu P., Hamou M.F., Hegi M.E. WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1. Oncogene. 2016;35:12–21. doi: 10.1038/onc.2015.61. PubMed DOI

Liu H., Lv Z., Guo E. Knockdown of long noncoding RNA SPRY4-IT1 suppresses glioma cell proliferation, metastasis and epithelial-mesenchymal transition. Int. J. Clin. Exp. Pathol. 2015;8:9140–9146. PubMed PMC

Cai H., Liu X., Zheng J., Xue Y., Ma J., Li Z., Xi Z., Li Z., Bao M., Liu Y. Long non-coding RNA taurine upregulated 1 enhances tumor-induced angiogenesis through inhibiting microRNA-299 in human glioblastoma. Oncogene. 2017;36:318–331. doi: 10.1038/onc.2016.212. PubMed DOI

Li J., Zhang M., An G., Ma Q. LncRNA TUG1 acts as a tumor suppressor in human glioma by promoting cell apoptosis. Exp. Biol. Med. 2016;241:644–649. doi: 10.1177/1535370215622708. PubMed DOI PMC

Yu H., Xue Y., Wang P., Liu X., Ma J., Zheng J., Li Z., Li Z., Cai H., Liu Y. Knockdown of long non-coding RNA XIST increases blood-tumor barrier permeability and inhibits glioma angiogenesis by targeting miR-137. Oncogenesis. 2017;6:e303. doi: 10.1038/oncsis.2017.7. PubMed DOI PMC

Wang P., Ren Z., Sun P. Overexpression of the long non-coding RNA MEG3 impairs in vitro glioma cell proliferation. J. Cell. Biochem. 2012;113:1868–1874. doi: 10.1002/jcb.24055. PubMed DOI

Gong X., Huang M. Long non-coding RNA MEG3 promotes the proliferation of glioma cells through targeting Wnt/beta-catenin signal pathway. Cancer Gene Ther. 2017;24:381–385. doi: 10.1038/cgt.2017.32. PubMed DOI

Zhang L., Liang X., Li Y. Long non-coding RNA MEG3 inhibits cell growth of gliomas by targeting miR-93 and inactivating PI3K/AKT pathway. Oncol. Rep. 2017;38:2408–2416. doi: 10.3892/or.2017.5871. PubMed DOI

Li J., Zhou L. Overexpression of lncRNA DANCR positively affects progression of glioma via activating Wnt/beta-catenin signaling. Biomed. Pharmacother. 2018;102:602–607. doi: 10.1016/j.biopha.2018.03.116. PubMed DOI

Shang C., Guo Y., Hong Y., Xue Y.X. Long Non-coding RNA TUSC7, a Target of miR-23b, Plays Tumor-Suppressing Roles in Human Gliomas. Front. Cell. Neurosci. 2016;10:235. doi: 10.3389/fncel.2016.00235. PubMed DOI PMC

Wang P., Liu Y.H., Yao Y.L., Li Z., Li Z.Q., Ma J., Xue Y.X. Long non-coding RNA CASC2 suppresses malignancy in human gliomas by miR-21. Cell Signal. 2015;27:275–282. doi: 10.1016/j.cellsig.2014.11.011. PubMed DOI

Liu Y., Xu N., Liu B., Huang Y., Zeng H., Yang Z., He Z., Guo H. Long noncoding RNA RP11-838N2.4 enhances the cytotoxic effects of temozolomide by inhibiting the functions of miR-10a in glioblastoma cell lines. Oncotarget. 2016;7:43835–43851. doi: 10.18632/oncotarget.9699. PubMed DOI PMC

Liu Q., Yu W., Zhu S., Cheng K., Xu H., Lv Y., Long X., Ma L., Huang J., Sun S., et al. Long noncoding RNA GAS5 regulates the proliferation, migration, and invasion of glioma cells by negatively regulating miR-18a-5p. J. Cell. Physiol. 2018 doi: 10.1002/jcp.26889. PubMed DOI

Zhao X., Liu Y., Zheng J., Liu X., Chen J., Liu L., Wang P., Xue Y. GAS5 suppresses malignancy of human glioma stem cells via a miR-196a-5p/FOXO1 feedback loop. Biochim. Biophys. Acta. 2017;1864:1605–1617. doi: 10.1016/j.bbamcr.2017.06.020. PubMed DOI

He Z., You C., Zhao D. Long non-coding RNA UCA1/miR-182/PFKFB2 axis modulates glioblastoma-associated stromal cells-mediated glycolysis and invasion of glioma cells. Biochem. Biophys. Res. Commun. 2018;500:569–576. doi: 10.1016/j.bbrc.2018.04.091. PubMed DOI

Fu C., Li D., Zhang X., Liu N., Chi G., Jin X. LncRNA PVT1 Facilitates Tumorigenesis and Progression of Glioma via Regulation of MiR-128-3p/GREM1 Axis and BMP Signaling Pathway. Neurotherapeutics. 2018 doi: 10.1007/s13311-018-0649-9. PubMed DOI PMC

Zhang X., Sun S., Pu J.K., Tsang A.C., Lee D., Man V.O., Lui W.M., Wong S.T., Leung G.K. Long non-coding RNA expression profiles predict clinical phenotypes in glioma. Neurobiol. Dis. 2012;48:1–8. doi: 10.1016/j.nbd.2012.06.004. PubMed DOI

Li R., Qian J., Wang Y.Y., Zhang J.X., You Y.P. Long noncoding RNA profiles reveal three molecular subtypes in glioma. CNS Neurosci. Ther. 2014;20:339–343. doi: 10.1111/cns.12220. PubMed DOI PMC

Kraus T.F., Greiner A., Guibourt V., Lisec K., Kretzschmar H.A. Identification of Stably Expressed lncRNAs as Valid Endogenous Controls for Profiling of Human Glioma. J. Cancer. 2015;6:111–119. doi: 10.7150/jca.10867. PubMed DOI PMC

Min W., Dai D., Wang J., Zhang D., Zhang Y., Han G., Zhang L., Chen C., Li X., Li Y., et al. Long Noncoding RNA miR210HG as a Potential Biomarker for the Diagnosis of Glioma. PLoS ONE. 2016;11:e0160451. doi: 10.1371/journal.pone.0160451. PubMed DOI PMC

Huttenhofer A., Vogel J. Experimental approaches to identify non-coding RNAs. Nucleic Acids Res. 2006;34:635–646. doi: 10.1093/nar/gkj469. PubMed DOI PMC

Cao Y., Wang P., Ning S., Xiao W., Xiao B., Li X. Identification of prognostic biomarkers in glioblastoma using a long non-coding RNA-mediated, competitive endogenous RNA network. Oncotarget. 2016;7:41737–41747. doi: 10.18632/oncotarget.9569. PubMed DOI PMC

Zhang X.Q., Sun S., Lam K.F., Kiang K.M., Pu J.K., Ho A.S., Lui W.M., Fung C.F., Wong T.S., Leung G.K. A long non-coding RNA signature in glioblastoma multiforme predicts survival. Neurobiol. Dis. 2013;58:123–131. doi: 10.1016/j.nbd.2013.05.011. PubMed DOI

Zhang X.Q., Kiang K.M., Wang Y.C., Pu J.K., Ho A., Cheng S.Y., Lee D., Zhang P.D., Chen J.J., Lui W.M., et al. IDH1 mutation-associated long non-coding RNA expression profile changes in glioma. J. Neurooncol. 2015;125:253–263. doi: 10.1007/s11060-015-1916-9. PubMed DOI

Zhi F., Wang Q., Xue L., Shao N., Wang R., Deng D., Wang S., Xia X., Yang Y. The Use of Three Long Non-Coding RNAs as Potential Prognostic Indicators of Astrocytoma. PLoS ONE. 2015;10:e0135242. doi: 10.1371/journal.pone.0135242. PubMed DOI PMC

Wang W., Yang F., Zhang L., Chen J., Zhao Z., Wang H., Wu F., Liang T., Yan X., Li J., et al. LncRNA profile study reveals four-lncRNA signature associated with the prognosis of patients with anaplastic gliomas. Oncotarget. 2016 doi: 10.18632/oncotarget.12624. PubMed DOI PMC

Hu L., Lv Q.L., Chen S.H., Sun B., Qu Q., Cheng L., Guo Y., Zhou H.H., Fan L. Up-Regulation of Long Non-Coding RNA AB073614 Predicts a Poor Prognosis in Patients with Glioma. Int. J. Environ. Res. Public Health. 2016;13:433. doi: 10.3390/ijerph13040433. PubMed DOI PMC

Jing S.Y., Lu Y.Y., Yang J.K., Deng W.Y., Zhou Q., Jiao B.H. Expression of long non-coding RNA CRNDE in glioma and its correlation with tumor progression and patient survival. Eur. Rev. Med. Pharmacol. Sci. 2016;20:3992–3996. PubMed

Zhou Y., Wang D.L., Pang Q. Long noncoding RNA SPRY4-IT1 is a prognostic factor for poor overall survival and has an oncogenic role in glioma. Eur. Rev. Med. Pharmacol. Sci. 2016;20:3035–3039. PubMed

Ma K.X., Wang H.J., Li X.R., Li T., Su G., Yang P., Wu J.W. Long noncoding RNA MALAT1 associates with the malignant status and poor prognosis in glioma. Tumour Biol. 2015;36:3355–3359. doi: 10.1007/s13277-014-2969-7. PubMed DOI

Wang W.A., Lai L.C., Tsai M.H., Lu T.P., Chuang E.Y. Development of a prediction model for radiosensitivity using the expression values of genes and long non-coding RNAs. Oncotarget. 2016;7:26739–26750. doi: 10.18632/oncotarget.8496. PubMed DOI PMC

Li H., Yuan X., Yan D., Li D., Guan F., Dong Y., Wang H., Liu X., Yang B. Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide. Cell. Physiol. Biochem. 2017;42:1192–1201. doi: 10.1159/000478917. PubMed DOI

Jia L., Tian Y., Chen Y., Zhang G. The silencing of LncRNA-H19 decreases chemoresistance of human glioma cells to temozolomide by suppressing epithelial-mesenchymal transition via the Wnt/beta-Catenin pathway. Onco-Targets Ther. 2018;11:313–321. doi: 10.2147/OTT.S154339. PubMed DOI PMC

Jiang C., Shen F., Du J., Fang X., Li X., Su J., Wang X., Huang X., Liu Z. Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression. Biomed. Pharmacother. 2018;97:844–850. doi: 10.1016/j.biopha.2017.10.146. PubMed DOI